Under $10 Biomerica Grows While Fighting COVID-19

The brutal race among biotech companies to finish off the pandemic and earn serious capital is still trendy. However, several investors hesitate in buying their stocks as some of them might not gain due to scientists’ failure, most of the time.

Gilead and Moderna have stocks that grew significantly in recent months making huge fortunes for visionary investors. Could Biomerica cheer its investors up by coming up with a successful vaccine for COVID-19 treatment? Time will show. There is no magic ball that tells the future.

Cash burning machine

Many young healthcare and biotech firms use funds from external sources to make their revenues lively. So, the same situation happens to Biomerica. Over $1 million revenue can’t increase the earnings unless major job cutting and admin expenses disappear within a quarter.

For the smart investor, income statement and balance sheet normally come as secondary factors when stock change mostly depends on scientists’ innovations.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life

Alex Krakowsky has 979 posts and counting. See all posts by Alex Krakowsky